Anna Zisman

Dr. Anna Zisman

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2017 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
AZAnna Zisman
Anna Zisman
Nephrolithiasis is highly prevalent across all demographic groups in the Western world and beyond, and its incidence rates are rising. In addition to the morbidity of the acute event, stone disease often becomes a lifelong problem that requires preventative therapy to diminish ongoing morbidity. Across the majority of stone types, increased fluid intake and targeted dietary modifications are mainstays of therapy. Specific dietary interventions associated with reduced calcium stone risk include adequate dietary calcium intake and restriction of sodium, protein, and oxalate intake, among others. Pharmaceutical therapy may be required if lifestyle changes are insufficient to minimize risk of stone recurrence, and must be targeted to the specific metabolic abnormalities portending risk for a given patient. Therapeutic options for idiopathic calcium stone disease include thiazides, citrate salts, and uric acid–lowering agents. Alkali salts are also the treatment of choice for uric acid stone disease. Management of struvite stone disease is largely surgical, but acetohydroxamic acid is a proven second line therapy. Cystinuria requires lifestyle modifications and may call for thiol-binding agents. Significant heterogeneity of the clinical population with stone disease has previously limited opportunities for large randomized controlled trials. However, as clinical phenotypes and genotypes are increasingly clarified, there are mounting opportunities for targeted randomized controlled trials in stone prevention. In the meantime, the currently available evidence for both lifestyle and pharmacologic interventions is reviewed herein.

25 February 2013 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
HXHongshi Xu
Hongshi Xu
AZAnna Zisman
Anna Zisman
FCFredric L Coe
Fredric L Coe
EWElaine M Worcester
Elaine M Worcester
Introduction: Kidney stones are a common problem worldwide with substantial morbidities and economic costs. Medical therapy reduces stone recurrence significantly. Much progress has been made in th...

1 December 2015 in Kidney International
Verified
Journal Article
Closed access
PDF file
AZAnna Zisman
Anna Zisman
AEAndrew P. Evan
Andrew P. Evan
FCFredric L. Coe
Fredric L. Coe
EWElaine M. Worcester
Elaine M. Worcester

19 June 2020 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
AZAnna Zisman
Anna Zisman
FCFredric L. Coe
Fredric L. Coe
ACAndrew J. Cohen
Andrew J. Cohen
CRChristopher B. Riedinger
Christopher B. Riedinger
EWElaine M. Worcester
Elaine M. Worcester
Background and objectives: Incidence of kidney stone disease is rising. It is not known whether mechanisms of stone formation differ across racial groups. Our objective was to identify differing lithogenic risk factors across racial groups in idiopathic nephrolithiasis. Design, setting, participants, & measurements: We conducted a retrospective cohort study evaluating metabolic risk factors in black and age-matched white idiopathic stone formers at our tertiary referral center. We compared serum and urine metabolic risk factors pre- and post-treatment across racial groups using analysis of covariance. Generalized linear modeling was used to build regression models for risk of stone formation in both groups. Results: Among 117 black and 172 white stone formers, urine volume was lower in black stone formers (1.4±0.8 versus 2.0±0.8 L/d, P<0.001). Urine calcium was lower in black stone formers (116±70 versus 217±115 mg/d, P<0.001). Supersaturations for calcium oxalate were similar among the groups, whereas calcium phosphate supersaturation was higher in white stone formers, and uric acid supersaturation was higher in black stone formers. Electrolyte free water clearance was significantly lower in black stone formers (207±780 versus 435±759 ml/d, P=0.02). In the subgroup of 77 black patients and 107 white patients with post-treatment evaluations, urine volume rose significantly and similarly in both groups. Urine sodium was unchanged in whites but increased in blacks by 40 mmol/d (95% confidence interval, 32 to 48 mmol/d). Electrolyte free water clearance remained lower in black stone formers (385±891 versus 706±893 ml/d, P=0.02). Post-treatment supersaturations were similar across the groups except for calcium phosphate, which improved with treatment in whites. Conclusions: Black stone formers have lower 24-hour urine calcium excretion and urine volume. Increases in urine volume with treatment were associated with increased solute, but not free water, excretion in black stone formers.

1 December 2021
Verified
Journal Article
Open access
NKNicholas S. Kowalczyk
Nicholas S. Kowalczyk
AZAnna Zisman
Anna Zisman
Cystinuria, accounting for about 1-2% of kidney stones in adults, carries significant morbidity beginning at a young age [1]. Cystine stone formers have more stone events compared to other stone formers, as well as more surgical interventions, potentially contributing to faster progression to chronic kidney disease (CKD), and end-stage kidney disease (ESKD) [2]. Successful medical therapy for cystine stone formers may be limited by adherence to the extensive lifestyle changes and the adverse side effect profiles of some interventions, leading to decreased quality of life for these patients relative to other stone formers.

20 November 2024 in Advances in Kidney Disease and Health
Verified
Journal Article
Closed access
MMMegan L Prochaska, MD, MPH
Megan L Prochaska, MD, MPH
AZAnna Zisman
Anna Zisman